Risk-benefit assessment of ivabradine in the treatment of chronic heart failure

Paweł Ptaszyński(Medical University of Lodz), Iwona Cygankiewicz(Medical University of Lodz), Irmina Urbanek(Medical University of Lodz), Krzysztof Kaczmarek(Medical University of Lodz)
Drug Healthcare and Patient Safety
April 1, 2014
10.2147/dhps.s43275
Cited by 6

Related Papers

Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension
|JAMA|2020|232
Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy
|EP Europace|2012|107
Quantitative Assessment of Microvolt T‐Wave Alternans in Patients with Congestive Heart Failure
|Journal of Cardiovascular Electrophysiology|2005|84
Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey
|EP Europace|2019|59
Ivabradine in Combination With Metoprolol Succinate in the Treatment of Inappropriate Sinus Tachycardia
|Journal of Cardiovascular Pharmacology and Therapeutics|2013|57